Press Conference & Analyst Meeting
Acquisition of CaridianBCT Holding Corp.
Terumo CorporationMarch 7, 2011
2
Target Company: CaridianBCT Holding Corp. (US)
Seller Company: Gambro AB (Sweden)
Purchase Price: US$2,625M in Cash
Anticipated Closing: April-May, 2011
Summary of Acquisition
3
Pursue Terumo’s Growth Strategy
4
M&A Strategy for “New growth opportunities”
Accelerate Growth strategy for 5 Fields of focus through Organic growth, Alliance and M&A
Global Leader
* May, 2010 IR Presentation
5 Fields of Focus
Transfusion as a key element of healthcare infrastructure
5
Another Growth Engine
May, 2010 IR Presentation
New Growth Engine
6
Purposes of Acquisition
Contribute to the expansion of healthcare worldwide
• Developed Countries: Aging populations
• Emerging Countries: Healthcare infrastructure development
Participate in specialized market growth
Significant synergy potential both in technologies and sales
• Products: Existing products and new technology
• Regions: From emerging countries to developed countries
Cardiac & Vascular Accelerate Innovations
Blood Transfusion To be a Global Leader
General Hospital Global Drug & Devices
Elderly Care, Post-acute Care
Diabetes Care Expanding Global Demand
Emerging Market China, India and Brazil
7
Corporate Growth Strategies
Blood Management Business
9
Blood Transfusion Market
Blood Transfusion is essential to Healthcare
Global demand for Blood Transfusion is expanding
Specialized market
Blood Collection
Centrifugation Storage Transfusion
Terumo Transfusion Products
Blood Bag System
Auto. Processing System Auto Blood Collection
Sterile Connection Welder
Auto Blood Collection
Pathogen ReductionWhole Blood Processing
Cell Expansion System
Launched in 2010
Therapeutic Apheresis
CaridianBCT Products
12
Overview of CaridianBCT
13※ Pre-Audit Data
Headquarters: Lakewood, Colorado, US (Private)
Finance: Sales: US$524M (FY2010)
CAGR12% (Ten years)
Operating Income: US$126M (FY2010)
Facilities: Branches in 32 CountriesPlants (US, UK)
Employees: approx. 2300 people
CEO: David Perez
※
14
Blood Bank Hospital / BiolabAutomated Collection
PRT Whole Blood Processes Cell Expansion System
Recently Launched
Esta
blish
ed m
arke
tsNew
ly Ente
red
Marke
ts
Therapeutic Apheresis
64% 24%
7%
※ Figures are Composition ratio
Customer Segments
15
Access to CaridianBCT’s innovative R&D
capabilities and novel high potential technologies
An innovative total solution company which provides Automated collection system, Disposable kit and software.
Focused on Platelet Market
64% of sales come from Automated Collections business. This core business focuses on high value products which allow blood banks to automatically collect any blood component, in any combination. As a result, CaridianBCT continues to add to its market leading position.
16
Effects of Acquisition
Terumo + CaridianBCT Blood Management Business
17
Create the Leading Global Provider to the Blood Transfusion Industry
(US$M) Europe US Japan ROW
CaridianBCT 170 260 20 80
Terumo 50 40 105 95
Total 220 300 125 175
Number One Player• Sales: US$820M
• Enhance Global Presence
• Competitive Products in
Platelet Segment
Regional Synergy• Among Emerging countries
to Developed countries
0
200
400
600
800
1000
Terumo
CaridianBCT
(US$M)
18
Aging Developed Counties• Increase in Cancer Therapies (Chemo/Radio) Increase in Platelet Demand
• Core business of CaridianBCT
Population Expansion and rising Medical Standard improvement in Emerging Countries• From Basics to High value-added Products
• Terumo + CaridianBCT = Full Range Products
Strong Growth in Blood Transfusion Market
Terumo
AutomatedSemi-AutomatedManual
DevelopedEmerging
CaridianBCT
Development in New Technologies
•Whole Blood Processing
•Pathogen Reduction
•Cell Expansion
20
One Big Step Forward for Globalization
Consolidation of both transfusion business
into one.
Obtain strong business management team
and global business infrastructures.
21
Effects of Acquisition
Create the leading global provider to the blood transfusion industry
Double Digit Growth in Growing Market
Evolve Terumo’s Global Management
22
Financial Impact
Impact on Earnings
• Details of the impact from goodwill and intangible asset will be announced once determined
Impact on EPS
• Accretive to EPS before amortization of goodwill by the end of fiscal year ending March, 2012
Shareholder Return
• Stable dividend level in the near term
23
This announcement contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘expects’, ‘expected’, ‘will’, ‘would’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, including but not limited to: (1) macroeconomic condition and general industry conditions such as the competitive environment for medical equipment business; (2) regulatory and litigation matters and risks; (3) legislative developments; (4) changes in tax and other laws and the effect of changes in general economic conditions; (5) the risk that a condition to closing of the Acquisition may not be satisfied; (6) the risk that a regulatory approval that may be required for the Acquisition is not obtained or is obtained subject to conditions that are not anticipated; and (7) other risks to consummation of the Acquisition. Terumo undertakes no obligation to publicly update any forward-looking statements after the date of this document.
Disclaimer regarding forward-looking statements
Top Related